U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

the only significant pairwise difference among those with obesity was that nutrition counseling rates were significantly ...

“BMI doesn’t account for factors like age, sex, race, ethnicity, bone density, overall body composition and muscle mass. It tends to overestimate obesity in shorter people and underestimate it in ...

Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...

The company's recent performance and future prospects have drawn significant attention from investors and analysts alike, particularly as it develops treatments in the highly competitive obesity ...

MariTide, Amgen's candidate for obesity treatment, has emerged as a focal point for investors. Phase II topline results are expected in late 2024, with analysts anticipating data that could position ...

Robert F. Kennedy Jr. can help to rebuild the systems that promote unhealthy lifestyles in America. He deserves our support.